# US 2023/0057153 A1 · Drug-coated medical devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057153 A1
- Document ID: US20230057153A1
- Status: Published application
- Kind: A1
- Application number: 17/849,426
- Filed: 2022-06-24
- Published: 2023-02-23
- Earliest claimed: 2015-07-09
- Assignees: Vascuros Medical (Shanghai) Co., Ltd.; Vascuros Medical Pte Ltd.
- Applicants: Vascuros Medical (Shanghai) Co., Ltd.; Vascuros Medical Pte Ltd.
- Inventors: Jingnan LUO; Qian Yi Michele LEE; Honglei WANG
- Web page: https://patentgrep.com/patent/US20230057153A1

## CPC

- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61L 29/085: {Macromolecular materials}
- A61M 25/1029: {Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril}
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/608: having two or more layers
- A61L 2300/62: Encapsulated active agents, e.g. emulsified droplets
- A61L 2300/622: Microcapsules
- A61L 2300/624: Nanocapsules
- A61L 2420/02: Methods for coating medical devices
- A61M 2025/1004: {Balloons with folds, e.g. folded or multifolded}
- A61M 2025/1031: {Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface}
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61M 2025/1075: {having a balloon composed of several layers, e.g. by coating or embedding}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Disclosed herein is a drug-coated medical device in the form of a balloon having an inner surface and an outer hydrophobic surface, an adhesion balance layer directly on the outer hydrophobic surface of the balloon, comprising a hydrophilic polymer and/or a hydrophilic compound where the hydrophilic compound has a molecular weight of less than 1,000 Daltons, and a therapeutic layer directly on the adhesion balance layer comprising a therapeutic agent and a pharmaceutically acceptable carrier, wherein the therapeutic agent is a hydrophobic therapeutic agent with one or more hydrogen-bonding groups and is provided as discrete drug particles in the therapeutic layer, the drug particles have at least one dimension that is less than 25 µm and are uniformly distributed on the surface of the balloon, and the pharmaceutically acceptable carrier is hydrophilic and has a molecular weight of less than 1,000 Daltons. A process to make the drug-coated medical device and uses thereof are also disclosed.

## Claims

### Claim 1

A drug-coated medical device comprising:
a balloon having an inner surface and an outer hydrophobic surface;
an adhesion balance layer directly on the outer hydrophobic surface of the balloon, comprising a hydrophilic polymer and/or a hydrophilic compound where the hydrophilic compound has a molecular weight of less than 1,000 Daltons; and
a therapeutic layer directly on the adhesion balance layer comprising a therapeutic agent and a pharmaceutically acceptable carrier, wherein:
the therapeutic agent is a hydrophobic therapeutic agent with one or more hydrogen-bonding groups and is provided as discrete drug particles in the therapeutic layer;
the drug particles have at least one dimension that is less than 25 µm and are uniformly distributed on the surface of the balloon; and
the pharmaceutically acceptable carrier is hydrophilic and has a molecular weight of less than 1,000 Daltons.

### Claim 2 (depends on 1)

The medical device according to claim 1, wherein the medical device is a catheter balloon for a balloon catheter or is a balloon catheter.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The medical device according to claim 1, wherein:
(a) the hydrophilic polymer and/or a hydrophilic compound in the adhesion balance layer contains hydrogen bonding moieties; and/or
(b) the drug particles have at least one dimension that is less than 15 µm (e.g. less than 10 µm); and/or
(c) one or more of the group selected from particulate needles, microparticles and nanoparticles.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The medical device according to claim 1 , wherein the adhesion balance layer swells or absorbs water when in contact with water.

### Claim at position 7

7-10. (canceled)

### Claim 11 (depends on 1)

The medical device according to claim 1 , wherein the adhesion balance layer further comprises a hydrophobic polymer.

### Claim 12 (depends on 11)

The medical device according to claim 11, wherein the polymer layer contains less than 30 wt% of the hydrophobic polymer and/or wherein the hydrophilic polymer and/or hydrophobic polymer is not shellac.

### Claim 13 (depends on 1)

The medical device according to claim 1 , wherein the hydrophilic polymer is a block copolymer comprising hydrophobic and hydrophilic blocks.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The medical device according to claim 1 , wherein the therapeutic agent of the therapeutic agent layer is selected from one or more of the group consisting of an antiproliferative, immunosuppressive, anti-angiogenic, anti-inflammatory, and anti-thrombotic agent.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The medical device according to claim 1 , wherein the adhesion balance layer further a therapeutic agent.

### Claim 18 (depends on 1)

The medical device according to claim 1 , wherein the hydrophilic compound with a molecular weight of less than 1,000 Daltons is selected from one or more of the group consisting of a sugar, a sugar alcohol, and polyethylene glycol.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The medical device according to claim 1 , wherein the pharmaceutically acceptable carrier is selected from one or more of the group consisting of tartaric acid, a sugar, and a sugar alcohol.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The medical device according to claim 20, wherein the pharmaceutically acceptable carrier is selected from one or more of the group consisting of xylitol and tartaric acid.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The medical device according to claim 1 , wherein the balloon forms an integral or removable part of a balloon catheter.

### Claim 26

A process to make a drug-coated medical devicecomprising:
a balloon having an inner surface and an outer hydrophobic
an adhesion balance layer directly on the outer hydrophobic surface of the balloon, comprising a hydrophilic polymer and/or a hydrophilic compound where the hydrophilic compound has a molecular weight of less than 1,000 Daltons; and
a therapeutic on the adhesion balance comprising a therapeutic agent and a pharmaceutically acceptable carrier, wherein:
the therapeutic agent is a hydrophobic therapeutic agent with one or more hydrogen-bonding groups and is provided as discrete drug particles in the therapeutic layer;
the drug particles have at least one dimension that is less than 25 µm and are uniformly distributed on the surface of the balloon; and
the pharmaceutically acceptable carrier is hydrophilic and has a molecular weight of less than 1,000 Daltons,
wherein the process comprises:
(a) providing an uncoated balloon;
(b) providing an adhesion balance layer precursor mixture, coating at least part of the outer surface of balloon with the adhesion balance layer precursor mixture to form an adhesion balance layer precursor layer and drying the adhesion balance layer precursor layer to provide a balloon coated with an adhesion balance layer;
(c) providing a therapeutic agent mixture and coating the therapeutic agent solution onto the outer surface of the balloon coated with an adhesion balance layer, followed by drying the coated balloon to provide the drug-coated catheter balloon, wherein
therapeutic agent mixture comprises a hydrophobic therapeutic agent with one or more hydrogen-bonding groups, a solvent and a hydrophilic pharmaceutically acceptable carrier that has a molecular weight of less than 1,000 Daltons; and
the adhesion balance layer precursor mixture comprises a hydrophilic polymer and/or a hydrophilic compound, where the hydrophilic compound has a molecular weight of less than 1,000 Daltons.

### Claim 27 (depends on 26)

The process according to claim 26, wherein the process further comprises the steps of:
(i) inflating the balloon between step (a) and (b);
(ii) deflating the balloon following step (c); and
(iii) folding the balloon following step (ii).

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The process according to claim 28 , wherein the adhesion balance layer precursor mixture further comprises a hydrophobic polymer.

### Claim at position 28

31-34. (canceled)

### Claim 35 (depends on 26)

The process according to claim 26, wherein:
(a) the medical device is a balloon catheter and the balloon is integrally formed as part of the balloon catheter; or
(b) the process further comprises fixing the balloon onto a balloon catheter either as a removable or integral part of said balloon catheter to form the medical device.

### Claim 36

(canceled)

### Claim 37

A method of treatment comprising administering an effective amount of a drug to a tissue in need of said treatment, wherein said administering involves contacting said tissue with a drug-coated medical device comprising:
a balloon having an inner surface and an outer hydrophobic surface;
an adhesion balance layer directly on the outer hydrophobic surface of the balloon, comprising a hydrophilic polymer and/or a hydrophilic compound where the hydrophilic compound has a molecular weight of less than 1,000 Daltons; and
a therapeutic layer directly on the adhesion balance layer comprising a therapeutic agent and a pharmaceutically acceptable carrier, wherein:
the therapeutic agent is a hydrophobic therapeutic agent with one or more hydrogen-bonding groups and is provided as discrete drug particles in the therapeutic layer;
the drug particles have at least one dimension that is less than 25 µm and are uniformly distributed on the surface of the balloon; and
the pharmaceutically acceptable carrier is hydrophilic and has a molecular weight of less than 1,000 Daltons .

### Claim 38 (depends on 37)

The method of treatment of claim 37, wherein the method further comprises the steps of:
(a) inserting the drug-coated medical device into a hollow tissue of a subject;
(b) advancing the medical device to a target site in a tissue;
(c) inflating the balloon and maintaining the inflated state for a period of time sufficient for the therapeutic agent to adhere to the target site;
(d) deflating the balloon and removing the medical device from the subject.

### Claim at position 33

39-43. (canceled)

### Claim 44 (depends on 1)

The drug-coated medical device according to claim 1, wherein:
the therapeutic layer comprises crystals of the therapeutic agent, and
the device is configured to release a sustainable therapeutically effective amount of the therapeutic agent from the therapeutic layer within a time period of 1 second to 2 minutes after reaching a desired site of action.
